Morgan Stanley raised the firm’s price target on Cytokinetics (CYTK) to $103 from $90 and keeps an Overweight rating on the shares. The firm sees the topline results from Cytokinetics’ ACACIA-HCM trial as “compelling” and supporting “a differentiated label,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Maxwell Skor Lifts Cytokinetics Price Target to $103 and Reiterates Buy on Strong Phase 3 ACACIA-HCM Results for Aficamten
- Cytokinetics Earnings Call Highlights Launch, Trial Wins
- Cytokinetics Highlights MYQORZO Progress and Cardiology Pipeline
- Analyst Maintains Buy Rating and $136 Price Target on Aficamten Following Strong Phase 3 ACACIA-HCM Results
- Morning News Wrap-Up, 5/5/26: Today’s Biggest Stock Market Stories!
